Personal care composition

Abstract

A personal care composition is disclosed, comprising moringa oil and coconut oil, wherein the weight ratio of the moringa oil to the coconut oil is at least 1.4:1.

Description

[Technical Field]

[0001] This invention relates to a personal care composition comprising moringa oil and coconut oil in a specific weight ratio. Surprisingly, it was found that the expression of the heme oxygenase 1 (HMOX1) gene is synergistically upregulated within this ratio range. [Background technology]

[0002] Human skin, through its barrier function, mechanical strength, and water impermeability, can provide physicochemical protection against environmental attacks. It is constantly exposed to harmful environmental and extreme conditions such as ultraviolet radiation, blue light, and pollution. Such exposure to harmful environments can lead to the excessive production of reactive oxygen species (ROS), thereby resulting in a state of oxidative stress. Oxidative stress can affect the skin in many ways, including signs of premature aging, such as wrinkles, fine lines, and uneven skin tone.

[0003] Heme oxygenase 1 (encoded by the HMOX1 gene) is known to play a protective role against oxidative stress. It is an enzyme that catalyzes the breakdown of heme into biliverdin, a precursor to bilirubin, a potent antioxidant metabolite with antioxidant and anti-inflammatory properties. Primarily functioning in heme catabolism, heme oxygenase 1 is a crucial cytoprotective enzyme with antioxidant, anti-inflammatory, and anti-apoptotic properties.

[0004] Stimulating the HMOX1 gene stimulates heme breakdown, which in turn provides anti-aging, antioxidant, and anti-inflammatory benefits. Human skin is also a site where inflammation, oxidative stress, and cell damage occur regularly.

[0005] Therefore, the inventors recognized the need to develop a personal care composition that can improve the expression of the HMOX1 gene, and developed a personal care composition containing moringa oil and coconut oil. Surprisingly, they found that when the weight ratio of moringa oil to coconut oil is at least 1.4:1, the expression of the HMOX1 gene can be significantly upregulated. [Overview of the project]

[0006] In a first aspect, the present invention relates to a personal care composition comprising moringa oil and coconut oil, wherein the weight ratio of moringa oil to coconut oil is at least 1.4:1.

[0007] In a second aspect, the present invention relates to a method for providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefits; reducing oxidative stress; and / or upregulating the expression of the heme oxygenase 1 gene, comprising the step of topically applying a composition of the present invention to the skin.

[0008] In a third aspect, the present invention relates to the use of the compositions of the present invention to provide antioxidant, anti-inflammatory, and anti-apoptotic benefits; to reduce oxidative stress; and / or to upregulate the expression of the heme oxygenase 1 gene.

[0009] All other aspects of the present invention will become more readily apparent upon consideration of the following detailed description and examples. [Modes for carrying out the invention]

[0010] Except as in the examples, or unless otherwise expressly indicated, all figures in this specification indicating the quantities or reaction conditions of materials, the physical properties of materials and / or their use may be understood to be modified by the word “approximately”.

[0011] All quantities are by weight of the composition unless otherwise specified.

[0012] Note that when specifying an arbitrary range of values, you can associate any specific upper limit with any specific lower limit.

[0013] To avoid misunderstanding, the word "comprising" is intended to mean "including," but not necessarily "consisting of" or "composed of." In other words, the listed steps or options do not need to be exhaustive.

[0014] The disclosures of the present invention as presented herein should be considered to encompass all embodiments found in the claims as multiple dependencies of one another, notwithstanding the fact that the claims may be found without multiple dependencies or redundancies.

[0015] If features are disclosed with respect to a particular aspect of the present invention (e.g., a composition of the present invention), such disclosure should be considered applicable to any other aspect of the present invention (e.g., a method of the present invention) with necessary modifications.

[0016] Typically, moringa oil contains or is moringa seed oil. Preferably, moringa oil is extracted from the seeds of at least one of the following species: Moringa oleifera, Moringa pterygosperma, Moringa peregrina, Moringa concanensis, or Moringa drouhardii. Moringa seeds are characterized by the presence of oil, the content of which can vary from 10 to 80%, preferably from 20 to 60%, depending on the species and maturity of the seed. In the case of Moringa oleifera, the oil content in Moringa oleifera seeds is in the range of 15 to 45%, preferably from 21 to 34%. To clarify, moringa oil is typically liquid at 25°C and atmospheric pressure.

[0017] Preferably, moringa oil is extracted from the seeds of Moringa oleifera. Preferably, moringa oil is extracted by cold pressing. Preferably, moringa oil is C 18-24 Contains fatty acids, and more preferably moringa oil is C 18-22 Moringa oil contains fatty acids, and more preferably, behenic acid.

[0018] Preferably, moringa oil is present in an amount of 0.0001 to 10% by weight of the composition, more preferably 0.005 to 5%, even more preferably 0.015 to 2%, even more preferably 0.03 to 0.6%, and most preferably 0.06 to 0.3%.

[0019] Preferably, moringa seed oil is present in an amount of 0.0001 to 10% by weight of the composition, more preferably 0.005 to 5%, even more preferably 0.015 to 2%, even more preferably 0.03 to 0.6%, and most preferably 0.06 to 0.3%.

[0020] Coconut oil is an edible extract obtained from the endosperm or flesh of mature coconuts harvested from coconut palms. Preferably, coconut oil comprises up to 85% by weight of the coconut oil of saturated fatty acids. The saturated fatty acids may comprise up to 48% by weight of the coconut oil of lauric acid.

[0021] Coconut oil can be produced by a dry process or a wet process. Preferably, coconut oil is produced by cold pressing. Coconut oil may be refined, hydrogenated, and / or fractionated.

[0022] In certain embodiments, the coconut oil is unrefined coconut oil. Preferably, the coconut oil is not refined, bleached, and / or deodorized. Furthermore, unrefined coconut oil is neither hydrogenated nor fractionated.

[0023] Preferably, the weight ratio of moringa oil to coconut oil ranges from 1.4:1 to 200:1, more preferably from 1.4:1 to 50:1, even more preferably from 1.4:1 to 20:1, and most preferably from 1.4:1 to 15:1. In certain embodiments, the weight ratio of moringa oil to coconut oil preferably ranges from 2.8:1 to 200:1, more preferably from 2.8:1 to 50:1, even more preferably from 2.8:1 to 15:1. In particularly preferred embodiments, the weight ratio of moringa oil to coconut oil preferably ranges from 2.8:1 to 8:1, more preferably from 2.8:1 to 6:1.

[0024] Preferably, the weight ratio of moringa seed oil to coconut oil is in the range of 1.4:1 to 200:1, more preferably 1.4:1 to 50:1, even more preferably 1.4:1 to 20:1, and most preferably 1.4:1 to 15:1. In a particular embodiment, the weight ratio of moringa seed oil to coconut oil is preferably in the range of 2.8:1 to 200:1, more preferably 2.8:1 to 50:1, and even more preferably 2.8:1 to 15:1. In a particularly preferred embodiment, the weight ratio of moringa seed oil to coconut oil is preferably in the range of 2.8:1 to 8:1, and more preferably 2.8:1 to 6:1.

[0025] Preferably, coconut oil is present in an amount of 0.00001 to 10% by weight of the composition, more preferably 0.0001 to 5%, even more preferably 0.001 to 2%, even more preferably 0.003 to 0.6%, and most preferably 0.01 to 0.2%.

[0026] The composition preferably contains a cleaning surfactant. Two or more cleaning surfactants may be included in the composition. The cleaning surfactant can be selected from soaps, non-soap anionic, cationic, nonionic, amphoteric surfactants, and mixtures thereof. Many suitable surface-active compounds are available and are well described in the literature, e.g., "Surface-Active Agents and Detergents," Volumes I and II, by Schwartz, Perry, and Berch. Preferred surface-active compounds that can be used are soaps, non-soap anionic surfactants, nonionic surfactants, amphoteric surfactants, or mixtures thereof.

[0027] Suitable non-soap anionic surfactants include linear alkylbenzene sulfonates, primary and secondary alkyl sulfates, particularly C8-C 15Examples include primary alkyl sulfates; alkyl ether sulfates; olefin sulfonates; alkyl xylene sulfonates; dialkyl sulfosuccinates; fatty acid ester sulfonates; or mixtures thereof. Sodium salts are generally preferred.

[0028] The most preferred non-soap anionic surfactants are linear alkylbenzene sulfonates, particularly C8-C8. 15 It is a linear alkylbenzene sulfonate having an alkyl chain length. Preferably, the level of the linear alkylbenzene sulfonate is 0% to 30% by weight of the total composition, more preferably 1% to 25% by weight, and most preferably 2% to 15% by weight.

[0029] Nonionic surfactants that can be used include primary and secondary alcohol ethoxylates, particularly C8-C8 ethoxylates ethoxylated with an average of 1-20 moles of ethylene oxide per mole of alcohol. 20 Aliphatic alcohols, more specifically C13, ethoxylated with an average of 1 to 10 moles of ethylene oxide per mole of alcohol. 10 ~C 15 Examples include primary and secondary aliphatic alcohols. Examples of non-ethoxylated nonionic surfactants include alkyl polyglycosides, glycerol monoethers, and polyhydroxyamides (glucamides). The level of the nonionic surfactant is preferably 0% to 30% by weight, preferably 1% to 25% by weight, and most preferably 2% to 15% by weight, based on the weight of the fully prepared composition containing the microcapsules of the present invention.

[0030] A suitable amphoteric surfactant is preferably a betaine surfactant. Examples of suitable amphoteric surfactants include, but are not limited to, alkylbetaines, alkylamidebetaines, alkylsulfobetaines, alkylsultaines, and alkylamidesultaines, which preferably have 8 to about 18 carbon atoms in the alkyl and acyl groups. The amount of amphoteric surfactant is preferably 0 to 20% by weight of the composition, more preferably 1 to 10% by weight.

[0031] The composition may also contain a specific monoalkyl cationic surfactant. As usable cationic surfactants, mention may be made of quaternary ammonium salts of the general formula R 1 R 2 R 3 R 4 N + X - , wherein the R groups are long or short hydrocarbon chains, typically alkyl, hydroxyalkyl or ethoxylated alkyl groups, and X is a counterion (for example, compounds where R 1 is a C8-C 22 alkyl group, preferably a C8-C 10 or C 12 -C 14 alkyl group, R 2 is a methyl group, and R 3 and R 4 , which may be the same or different, are methyl groups or hydroxyethyl groups); and cationic esters (for example, choline esters).

[0032] Water-insoluble skin-benefiting substances may also be incorporated into the composition as conditioners and moisturizers. Examples include silicone oils; hydrocarbons such as liquid paraffin, petrolatum, microcrystalline wax and mineral oil; and vegetable triglycerides such as sunflower seed oil and cottonseed oil.

[0033] Some compositions may contain thickeners. These may be selected from, but are not limited to, cellulose compounds, natural gums, and acrylic polymers. Among the cellulose compounds are sodium carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, and combinations thereof. Suitable gums include xanthan gum, pectin, karaya, agar, alginate gum, and combinations thereof. Preferably, the composition contains acrylic polymers, preferably homopolymers and copolymers of acrylic acid and methacrylic acid. Among the acrylic polymer thickeners are homopolymers and copolymers of acrylic acid and methacrylic acid, and include carbomers such as Carbopol 1382, Carbopol 982, Ultrez, Aqua SF-1, and Aqua SF-2, available from Lubrizol Corporation. The amount of thickener may range from 0.01 to 3% by weight of the active polymer (excluding solvent or water) in the composition.

[0034] Preferably, preservatives can be incorporated into the compositions of the present invention to protect against the growth of potentially harmful microorganisms. Conventional preservatives suitable for the compositions of the present invention are alkyl esters of para-hydroxybenzoic acid. Other preservatives that have come into use more recently include hydantoin derivatives, propionates, and various quaternary ammonium compounds. Particularly preferred preservatives are phenoxyethanol, methylparaben, propylparaben, imidazolidinyl urea, sodium dehydroacetate, and benzyl alcohol. The preservative should be selected considering the use of the composition and any possible incompatibility between the preservative and other components. The preservative is preferably used in an amount ranging from 0.01% to 2% by weight of the composition.

[0035] Various other optional materials can be incorporated into the composition. These may include antimicrobial agents, such as 2-hydroxy-4,2',4'-trichlorodiphenyl ether (triclosan), 2,6-dimethyl-4-hydroxychlorobenzene, and 3,4,4'-trichlorocarbanilide; scrubbing and exfoliating particles, such as polyethylene and silica or alumina; cooling agents, such as menthol; skin soothing agents, such as aloe vera; and colorants.

[0036] Furthermore, the compositions of the present invention may further contain 0.5 to 10% by weight of a metal ion chelating agent, such as tetrasodium ethylenediaminetetraacetate (EDTA), EHDP, or a mixture thereof; an opacifying agent and a pearlizer, such as ethylene glycol distearate, titanium dioxide, or Lytron 621 (styrene / acrylate copolymer); all of which are useful for improving the appearance or properties of the product.

[0037] The composition may contain water in an amount of 10-90%, more preferably 20-85%, even more preferably 25-78%, and most preferably 32-65% by weight of the composition.

[0038] Preferably, the composition is about 20 seconds -1 When measured at 20°C with a relatively high shear rate, it has a viscosity of at least 10 mPa·s, more preferably in the range of 30 to 10000 mPa·s, even more preferably 50 to 5000 mPa·s, and most preferably 100 to 2000 mPa·s. Preferably, the composition is in fluid form at atmospheric pressure and 25°C.

[0039] Preferably, the personal care composition is a skin care composition. As used herein, the term “skin” includes the skin of the face, neck, chest, abdomen, back, arms, armpits, hands, and legs. Preferably, “skin” includes the skin of the face and armpits, and more preferably, skin means the skin of the face excluding the lips and eyelids.

[0040] Preferably, the method is non-therapeutic. Preferably, the use is non-therapeutic. The term non-therapeutic is used for cosmetic purposes and not for curative or therapeutic purposes.

[0041] The present invention also provides a composition comprising moringa oil and coconut oil, wherein the weight ratio of moringa oil to coconut oil is at least 1.4:1, for use in providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefits; reducing oxidative stress; and / or upregulating the expression of the heme oxygenase 1 gene.

[0042] The present invention also provides for the use in the manufacture of a combination of moringa oil and coconut oil, wherein the weight ratio of moringa oil to coconut oil is at least 1.4:1, to provide antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefits; reduction of oxidative stress; and / or upregulation of heme oxygenase 1 gene expression.

[0043] Preferably, the composition can upregulate the expression of the heme oxygenase 1 (HMOX1) gene by at least 1.9 times, more preferably 1.9 to 6 times, even more preferably 2 to 5 times, even more preferably 2.7 to 4.5 times, and most preferably 3.3 to 4 times, compared to a personal care composition that typically does not contain either moringa oil or coconut oil.

[0044] The following embodiments are provided to facilitate understanding of the present invention. The embodiments are not intended to limit the scope of the claims.

[0045] [Examples] [Example 1] This example demonstrates the preparation of a personal care composition containing moringa seed oil and coconut oil. [Table 1]

[0046] A series of personal care compositions were prepared according to Table 1 using the following standard procedure.

[0047] [Example 2] This example demonstrates the ability of various personal care compositions to upregulate HMOX1 gene expression.

[0048] ArchSkin living skin equivalent (LSE) is a 3D reconstructed human epidermal model using Chinese human keratinocytes supplied by Archgene (Shanghai, China) and cultured at a gas-liquid interface in a prescribed serum-free medium. Squalene monohydroperoxide (SQOOH), a stress surrogate, was prepared in-house by exposing squalene to sunlight irradiation in the presence of a sensitizer.

[0049] The sample was diluted in phosphate-buffered saline (PBS) in a 1:1 volume ratio. SQOOH was diluted with squalene to a 1% by weight concentration. 10 μL of diluted SQOOH was applied topically to the LSE and left for 30 seconds. The LSE was then treated with 10 μL of the diluted sample for another 30 seconds and gently rinsed with 20 mL of PBS. After 24 hours, tissue was collected for gene expression analysis.

[0050] The extracted RNA was quantified using a Nanodrop spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) and reverse transcribed to generate template cDNA using Evo M-MLV RT Premix for qPCR (Accurate Biotechnology, catalog: AG11706) according to the manufacturer's protocol. HMOX1 gene expression was analyzed by polymerase chain reaction (PCR) using the SYBR® Green Premix Pro Taq HS qPCR Kit (Accurate Biotechnology, AG11701). The actin beta (ACTB) gene was selected as a housekeeping gene, and all data regarding the relative expression of the target gene were normalized relative to the ACTB gene. The fold change in expression was calculated compared to a blank control (culture medium without the active substance). All tests were performed at least three times, and the fold changes in HMOX1 gene expression are shown in Table 1.

[0051] The results are summarized in Table 2. [Table 2]

[0052] The data in Table 1 clearly shows that samples 1, 2, and 3 can significantly increase HMOX1 gene expression more than samples A, B, or C. Sample 1 is significantly superior to sample 3 in increasing HMOX1 gene expression, and sample 2 is significantly superior to both samples 1 and 3 in increasing HMOX1 gene expression.

Claims

1. A personal care composition comprising moringa oil and coconut oil, wherein the weight ratio of the moringa oil to the coconut oil is at least 1.4:

1.

2. The composition according to claim 1, wherein the moringa oil comprises or is moringa seed oil.

3. The composition according to claim 2, wherein the moringa oil is extracted from the seeds of Moringa oleifera.

4. The composition according to any one of claims 1 to 3, wherein the moringa oil is present in an amount of 0.0001 to 10%, more preferably 0.015 to 2%, of the composition by weight.

5. The composition according to any one of claims 1 to 4, wherein the coconut oil is unrefined coconut oil.

6. The composition according to any one of claims 1 to 5, wherein the coconut oil has not been hydrogenated or fractionally distilled.

7. The composition according to any one of claims 1 to 6, wherein the weight ratio of the moringa oil to the coconut oil is in the range of 1.4:1 to 50:1, preferably 1.4:1 to 15:1, and more preferably 2.8:1 to 8:

1.

8. The composition according to any one of claims 1 to 7, wherein the weight ratio of the moringa seed oil to the coconut oil is in the range of 1.4:1 to 50:1, preferably 1.4:1 to 15:1, and more preferably 2.8:1 to 8:

1.

9. The composition according to any one of claims 1 to 8, wherein the coconut oil is present in an amount of 0.00001 to 10%, preferably 0.003 to 0.6%, of the composition by weight.

10. The composition according to any one of claims 1 to 9, wherein the composition contains water in an amount of 25 to 78% by weight of the composition.

11. A method for providing antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefits; reducing oxidative stress; and / or upregulating the expression of the heme oxygenase 1 gene, comprising the step of topically applying a composition according to any one of claims 1 to 10 to the skin.

12. Use of the composition according to any one of claims 1 to 11 to provide antioxidant, anti-inflammatory, anti-apoptotic and / or anti-aging benefits; to reduce oxidative stress; and / or to upregulate the expression of the heme oxygenase 1 gene.

Images